Transformation Clinical Trials

17 recruitingLast updated: June 18, 2026

There are 17 actively recruiting transformation clinical trials across 11 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Chicago, Illinois, United States, Chapel Hill, North Carolina, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Transformation Trials at a Glance

17 actively recruiting trials for transformation are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Chicago, Chapel Hill, and Boston. Lead sponsors running transformation studies include German CLL Study Group, Beijing University of Chinese Medicine, and BeiGene.

Browse transformation trials by phase

Treatments under study

About Transformation Clinical Trials

Looking for clinical trials for Transformation? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Transformation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Transformation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1

CD45BE-HSPC + CART-45 Cells

Hodgkin LymphomaRichter's TransformationT-cell Non-Hodgkin Lymphoma+1 more
University of Pennsylvania42 enrolled1 locationNCT07451054
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

ONO-4538 Study in Patients With Richter's Transformation

Richter's Transformation
Ono Pharmaceutical Co., Ltd.14 enrolled10 locationsNCT06936943
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Phase 2

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Chronic Lymphocytic LeukemiaRichter's Transformation
Christine Ryan70 enrolled5 locationsNCT06043674
Recruiting
Not Applicable

Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization for Variceal Bleeding in Cavernous Transformation of Portal Vein.

Cavernous Transformation of Portal VeinGastroesophageal Varices Bleeding
Air Force Military Medical University, China26 enrolled1 locationNCT07310316
Recruiting

Registry of the German CLL Study Group

CLLT-LGL LeukemiaNK-LGL Leukemia+5 more
German CLL Study Group8,000 enrolled1 locationNCT02863692
Recruiting
Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 3

Thrombolysis in Factor Xa-inhibitors Trial

StrokeAcute Ischemic StrokeIschemic Stroke+6 more
Guri Hagberg300 enrolled13 locationsNCT06878066
Recruiting
Phase 2

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+5 more
Miltenyi Biomedicine GmbH248 enrolled25 locationsNCT04792489
Recruiting
Phase 2

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

Richter Transformation
German CLL Study Group83 enrolled11 locationsNCT04271956
Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666
Recruiting

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation
Beijing University of Chinese Medicine2,000 enrolled2 locationsNCT03261934
Recruiting
Phase 2

A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Non Hodgkin's Disease in remissionAcute Myeloid Leukaemia in first or second complete remissionacute Lymphoblastic Leukaemia in first or second complete remission+7 more
St Vincent's Hospital Sydney70 enrolled6 locationsACTRN12617000151336